FIBRATES AND STATINS IN THE TREATMENT OF HYPERLIPIDEMIA - AN APPRAISAL OF THEIR EFFICACY AND SAFETY

被引:123
作者
SHEPHERD, J
机构
[1] Institute of Biochemistry, Royal Infirmary, Glasgow
关键词
CHD PREVENTION; CONTINUED HYPOLIPEMIC DRUG THERAPY; MYOPATHY;
D O I
10.1093/eurheartj/16.1.5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:5 / 13
页数:9
相关论文
共 70 条
[1]   THE FIBRINOLYTIC SYSTEM AND COAGULATION DURING BEZAFIBRATE TREATMENT OF HYPERTRIGLYCERIDEMIA [J].
ALMER, LO ;
KJELLSTROM, T .
ATHEROSCLEROSIS, 1986, 61 (01) :81-85
[2]  
[Anonymous], 1992, NUTR METAB CARDIOVAS, V2, P113
[3]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[4]   LOVASTATIN AND RHABDOMYOLYSIS [J].
AYANIAN, JZ ;
FUCHS, CS ;
STONE, RM .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (08) :682-683
[5]   MODE OF ACTION OF LIPID-LOWERING AGENTS, CLOFIBRATE AND BM-15075, ON CHOLESTEROL-BIOSYNTHESIS IN RAT-LIVER [J].
BERNDT, J ;
GAUMERT, R ;
STILL, J .
ATHEROSCLEROSIS, 1978, 30 (02) :147-152
[6]   LONG-TERM SAFETY AND EFFICACY PROFILE OF SIMVASTATIN [J].
BOCCUZZI, SJ ;
BOCANEGRA, TS ;
WALKER, JF ;
SHAPIRO, DR ;
KEEGAN, ME .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (11) :1127-1131
[7]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[8]  
CHAIT A, 1980, EUR J CLIN INVEST, V10, P17, DOI 10.1111/j.1365-2362.1980.tb00004.x
[9]  
CHICHMANIAN RM, 1991, ANN MED INTERNE, V142, P587
[10]   LOVASTATIN GEMFIBROZIL MYOPATHY - A CLINICAL, HISTOCHEMICAL, AND ULTRASTRUCTURAL-STUDY [J].
CHUCRALLAH, A ;
DEGIROLAMI, U ;
FREEMAN, R ;
FEDERMAN, M .
EUROPEAN NEUROLOGY, 1992, 32 (05) :293-296